No Data
Jenkem Technology's Unit Completes Enrollment of First Subject for Polyethylene Glycol Irinotecan for Injection Trial
Jenkem Technology (688356.SH): The first subject enrolled in the phase II clinical trial of Polyethylene Glycol Iletocan used to treat triple-negative breast cancer with brain metastases.
Gelonghui November 12th, Jenkem Technology (688356.SH) announced that the independently developed injection polyethylene glycol irinotecan (pharmaceutical code: JK1201I) for the treatment of brain metastasis associated triple-negative breast cancer phase II clinical trial "JK1201I treatment of triple-negative breast cancer II clinical study with brain metastasis" has recently completed the enrollment of the first subject.
After the Recent Decline, Jenkem Technology Co., Ltd. (SHSE:688356) CEO Xuan Zhao's Holdings Have Lost 11% of Their Value
2024 THIRD QUARTER REPORT (CORRECTED)
Corrections to the 2024 Third Quarter Report
Jiankai Technology: Third quarter report 2024
Should Weakness in Jenkem Technology Co., Ltd.'s (SHSE:688356) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?
No Data
